<DOC>
	<DOCNO>NCT00114270</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming , grow , come back . Estrogen cause growth breast cancer cell . Hormone therapy use letrozole may prevent breast cancer lower amount estrogen body make . Zoledronate may prevent bone loss cause letrozole . Giving letrozole together zoledronate may prevent breast cancer reduce bone loss . PURPOSE : This randomized clinical trial study letrozole zoledronate see well work compare letrozole placebo placebo alone treat healthy postmenopausal woman high breast density .</brief_summary>
	<brief_title>Letrozole With Without Zoledronate Treating Healthy Postmenopausal Women With High Breast Density</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare percent change breast density healthy postmenopausal woman high breast density treat placebo vs letrozole placebo v letrozole zoledronate . - Compare percent change biochemical marker bone turnover participant treat regimen . Secondary - Compare bone density participant treat regimen . - Compare growth hormone release insulin-like growth factor level participant treat regimen . - Compare incidence severity adverse event participant treat regimen . OUTLINE : This randomize , placebo-controlled , double-blind , multicenter , pilot study . Participants stratify accord prior hormone replacement therapy ( HRT ) use ( discontinue HRT &gt; 5 year ago prior HRT use v discontinue HRT 1-5 year ago ) . Patients randomize 1 3 treatment arm . - Arm I : Participants receive oral placebo daily 12 month placebo IV 15 minute day 0 6 month . - Arm II : Participants receive oral letrozole daily 12 month placebo IV 15 minute day 0 6 month . - Arm III : Participants receive oral letrozole daily 12 month zoledronate IV 15 minute day 0 6 month . In arm , treatment continue absence unacceptable toxicity . After completion study treatment , participant follow 3 month . PROJECTED ACCRUAL : A total 120 participant ( 40 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Healthy participant Postmenopausal &gt; 5 year Breast density ≥ 50 % digitize mammography No history breast cancer , breast implant , gynecological malignancy No osteoporosis postmenopausal fracture Tscores ≥ 2.0 dualenergy xray absorptiometry ( DEXA ) scan PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status See Disease Characteristics Performance status ECOG 01 Life expectancy Not specify Hematopoietic Not specify Hepatic AST ALT ≤ 3 time normal Renal Creatinine ≤ 1.5 mg/dL Cardiovascular No cardiac disease Other Nonsmoker Vitamin D ≥ 15 ng/mL No history chronic medical psychiatric condition laboratory abnormality would preclude study compliance participation No alcohol consumption &gt; 2 alcoholic drink per day No malabsorption PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy At least 1 year since prior hormone replacement therapy No concurrent steroid , parathyroid hormone , raloxifene Radiotherapy Not specify Surgery Not specify Other No concurrent medication know affect calcium bone metabolism ( e.g. , anticoagulant , antiseizure medication , bisphosphonates , calcitonin )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>osteoporosis</keyword>
</DOC>